Tbc2130 - Latest News2026-07-19T01:22:47+00:00urn:uuid:6dbe0c4c-3a0a-adcc-9532-28071a8568a2When DNA Has Nothing to Say, RNA Speaks: How OncoDxRx's PGA Assay Is Rewriting the Rules of Precision Oncologyurn:uuid:113ea453-bbaa-0235-72f9-330525d3254b2026-07-13T00:52:57+00:00Game-changing gene signature tool accurately predicts how cancer patients will respond to the existing cancer drugsurn:uuid:3ce43b95-7524-80fb-76f7-ad173e4017a02025-08-09T23:19:28+00:00Solving the equations of cancer cell vulnerabilityurn:uuid:72a1f332-e319-a341-4a7f-0097872083fe2025-07-30T22:54:55+00:00Beyond DNA sequencing, the revolutionary OncoDxRx’s MRD monitoring OncoMRD assay delivers on its promisesurn:uuid:a7a6babe-ba34-bbdb-49eb-91394762c6d62025-07-28T21:32:42+00:00OncoDxRx Reveals New Breakthrough OncoMRD BREAST Testurn:uuid:6e144e75-f5b9-5241-e172-c58586f136492025-07-14T18:12:17+00:00OncoDxRx tests PGA on real-world patients, eyes drug response prediction technology leapurn:uuid:f2aaf67d-f61f-5ef6-4fa8-b03f785030302025-04-16T21:06:05+00:00OncoMRD: OncoDxRx's multi-spectral integrated gene panel for monitoring residual disease in solid tumorurn:uuid:1aeae872-d5f2-7ccf-0c9b-9e66fb38b1372025-04-04T22:45:08+00:00OncoDxRx fortifies residual tumor monitoring arsenal amid rising cancer threatsurn:uuid:9c82984f-d7da-75f0-3e92-f377b80c083f2025-03-29T20:03:36+00:00Unprecedented Drug Mapping Technology Provides Clues for Precision Treatment of Non-respondersurn:uuid:c086e4fb-144f-cc04-0eea-0848cb8bf33e2025-03-20T23:09:03+00:00From Bench to Breakthrough: Translating Gene Signature into Life-Changing Therapiesurn:uuid:3e27fc41-b016-77a2-bc10-7836a32bba9e2025-03-15T20:54:44+00:00OncoDxRx to wield game-changing technologies in the fight of cancerurn:uuid:c14c3999-35fd-0446-b59a-ad1cb94677582025-03-09T00:08:21+00:00OncoDxRx's precision diagnostics innovations: efficiency, economy and personalizationurn:uuid:df9560e9-abbc-1ddd-5f4a-b58d1c1f69e22025-02-28T22:48:44+00:00PGA vs. Biomarker Testing: Which Platform Reigns Supreme?urn:uuid:15eafb64-536e-b4a9-9018-ffb8b314f16d2025-02-22T20:21:15+00:00Patient-Derived Gene Expression Signatures Are Pioneering Residual Tumor Monitoringurn:uuid:758ce4ed-e64a-748d-a13a-7819f14422cd2025-02-14T23:24:27+00:00OncoDxRx Responds to Growing Cancer Threat with Cutting-Edge Capabilitiesurn:uuid:e99f16ed-4cd0-01f4-043c-16595ead81532025-02-11T00:31:42+00:00OncoMRD: OncoDxRx Now Has One of Best Technology for Monitoring Residual Diseaseurn:uuid:244aa3c6-ebe8-88e9-f70d-8c79b1952b872025-02-01T23:31:04+00:00OncoDxRx Draws Lessons from Precision Medicine to Address Modern Cancer Threatsurn:uuid:b0aa009e-a0c5-30ec-d7f7-a8937ad8d1a92025-01-29T00:04:28+00:00Improving patient treatment outcomes using cfmRNA-based OncoMRD analysisurn:uuid:1defc946-7edc-f632-93d8-0529dbdd06f42025-01-11T22:48:41+00:00OncoDxRx Unveils a Decentralized Future for Personalized Medicineurn:uuid:5ba7a6cd-bdcc-7093-da45-6ea6de27c2d32025-01-07T23:48:18+00:00A responsibility to patients: close the biomarker testing gap in precision oncologyurn:uuid:1a7057ec-fda2-89d7-64f8-6c1955a798c22024-12-24T23:56:53+00:00Meet OncoDxRx's PGA: A 21st Century Technology Ahead Of Its Timeurn:uuid:d3550cd6-23e1-b207-7a12-b46927bd79ca2024-12-05T23:50:32+00:00Gene Signature Could Predict Drug Response for Non-Small Cell Lung Cancerurn:uuid:31856891-e1e8-a04e-4127-71f301e5c1aa2024-11-19T02:43:11+00:00OncoDxRx claims their new technology is most powerful to predict drug efficacyurn:uuid:4314da42-120f-53bd-f4ba-96b2714245332024-11-15T00:26:39+00:00OncoDxRx Enters Molecular Residual Disease Market with Its Exclusive OncoMRD Testurn:uuid:6832f7cc-ee28-82ed-c051-9eaa9160bdba2024-11-11T23:24:30+00:00Breakthrough Technology Predicts Drug Responses in People with Cancerurn:uuid:7ba3f2c3-19a9-42dc-533a-9242e5044a8d2024-11-03T23:48:04+00:00OncoDxRx's blood test shows the benefits of drug efficacy prediction for non-respondersurn:uuid:1e07804e-d2f0-0ad7-6460-72afc104bd1e2024-10-27T20:42:35+00:00OncoDxRx’s PGA technology accurately predicted drug efficacy in non-responder patientsurn:uuid:31ecd889-66bf-163e-60d6-002d2d255dde2024-10-20T00:10:58+00:00Emphasis on off-label cancer treatment for non-responders is a must, OncoDxRx saysurn:uuid:1d4c8249-94b0-bf11-1551-96927b72744b2024-10-11T18:55:33+00:00OncoDxRx launches drug response prediction technology for therapeutic non-responders in world firsturn:uuid:bb593159-7817-b133-8394-4771db5dc3612024-10-07T22:58:23+00:00OncoDxRx to personalize off-label cancer drugs for patients who have run out of treatment optionsurn:uuid:a70727b2-899a-005f-4548-a9084055c06d2024-09-18T22:05:36+00:00New Technology Based on Gene Expression Could Identify Effective Drugs for Non-Responders in Cancerurn:uuid:55393588-08a6-b923-e6bf-df4f9398e3ea2024-09-07T21:41:12+00:00One-Of-A-Kind Technology, PGA, Predicts Drug Responseurn:uuid:eaa4d42c-1033-d9e8-509e-a55265496dd72024-08-22T22:24:42+00:00OncoDxRx aims to expand its exclusive liquid biopsy technology into monitoring residual diseaseurn:uuid:c7788718-7f6d-f0fb-03d5-df801821f2662024-08-18T20:25:02+00:00PGA and OncoMRD technology breakthroughs, showing the teeth of OncoDxRx’s liquid biopsy umbrellaurn:uuid:86ea3e63-1c0a-be50-f8ca-2fa91d0dab072024-08-11T21:31:03+00:00A Gene-to-Drug Renaissanceurn:uuid:b0487df6-8c1f-3646-b3c5-88f1711202682024-08-03T01:18:28+00:00PGA from OncoDxRx gives personalized cancer solutionsurn:uuid:bb692983-b430-0bfd-6bf9-578ed1e36a142024-07-31T22:39:07+00:00OncoDxRx Harnesses Tumor Gene Expression to Predict Drug Efficacyurn:uuid:18e49771-1735-20fc-42d5-d9df3776d3a12024-07-28T21:40:30+00:00PGA drug response prediction with 360-degree Dx and Rx analyticsurn:uuid:0f56e024-0612-33e9-a8c6-5241b06ded5c2024-07-20T22:47:59+00:00OncoDxRx Seeks 2024 IOC For Molecular Residual Disease Capability For Solid Tumorurn:uuid:41bdaf48-8869-6d91-9b4c-3e2c914ce8642024-06-28T23:20:39+00:00AI Isn’t the Magic Bullet to Simplify Drug Discoveryurn:uuid:a3bddbb1-1fc5-bde4-b8cd-1c2178e559a22024-06-11T23:25:36+00:00OncoDxRx’s invisible battle to counter jamming from tumor cellsurn:uuid:099d7763-1c89-0d93-4bde-719a5472303f2024-06-03T03:01:34+00:00PGA Technology Broadens and Quickens Precision Treatment Option for Unresponsive Cancer Patientsurn:uuid:73384eef-ee72-6427-9bb2-04cfb146eb942024-05-23T00:04:11+00:00Personalized cancer treatments based on PGA testing quickly leads to faster treatment, better outcomesurn:uuid:c65f08df-be89-201d-79d4-dc8f03206ad22024-05-15T00:00:31+00:00Reveal of OncoDxRx’s drug response prediction technology stirs up industryurn:uuid:f5d7fac8-9cbe-348e-44b5-9f39222e28c22024-04-07T20:55:05+00:00Cancer treatment could be transformed by cutting-edge PGA technologyurn:uuid:eee8db7b-0a9a-db5a-d82f-932a79fc31cf2024-03-24T01:03:38+00:00PGA drug response prediction could help us to stay one step ahead of the diseaseurn:uuid:d27cb9b4-cc3a-cab1-8953-3d0fb79e8e8c2024-03-21T19:56:24+00:00PGA helps predict anticancer drug response in a weekurn:uuid:1b184d07-29da-c6c8-b183-cb15d55b2a7c2024-03-18T00:50:57+00:00Targeted gene expression signature paves the way for new cancer treatmentsurn:uuid:ca1786bb-b86d-f69e-faf5-2c91abe4fe372024-03-10T00:05:49+00:00Addressing Barriers to Implementing MRD Testing in Community Oncology Practicesurn:uuid:7bd2f132-3a4f-ba9e-0bcc-05b1b0a1b4e72024-03-05T19:58:42+00:00Employing PGA to Optimize Treatment Selectionurn:uuid:7864d2ef-be62-e8a3-1825-a63b365781b22024-02-28T20:30:33+00:00